Annual EBITDA:
-$290.98M-$330.87M(-829.45%)Summary
- As of today, AMLX annual EBITDA is -$290.98 million, with the most recent change of -$330.87 million (-829.45%) on December 31, 2024.
- During the last 3 years, AMLX annual EBITDA has fallen by -$208.34 million (-252.12%).
- AMLX annual EBITDA is now -829.45% below its all-time high of $39.89 million, reached on December 31, 2023.
Performance
AMLX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$35.91M+$6.81M(+15.94%)Summary
- As of today, AMLX quarterly EBITDA is -$35.91 million, with the most recent change of +$6.81 million (+15.94%) on September 30, 2025.
- Over the past year, AMLX quarterly EBITDA has increased by +$3.33 million (+8.49%).
- AMLX quarterly EBITDA is now -275.31% below its all-time high of $20.48 million, reached on June 30, 2023.
Performance
AMLX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$156.76M+$3.33M(+2.08%)Summary
- As of today, AMLX TTM EBITDA is -$156.76 million, with the most recent change of +$3.33 million (+2.08%) on September 30, 2025.
- Over the past year, AMLX TTM EBITDA has increased by +$55.28 million (+26.07%).
- AMLX TTM EBITDA is now -492.99% below its all-time high of $39.89 million, reached on December 31, 2023.
Performance
AMLX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AMLX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -829.5% | +8.5% | +26.1% |
| 3Y3 Years | -252.1% | +34.1% | +15.1% |
| 5Y5 Years | -2239.0% | -318.0% | -1724.8% |
AMLX EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -829.5% | at low | -275.3% | +70.5% | -493.0% | +38.5% |
| 5Y | 5-Year | -829.5% | at low | -275.3% | +70.5% | -493.0% | +38.5% |
| All-Time | All-Time | -829.5% | at low | -275.3% | +70.5% | -493.0% | +38.5% |
AMLX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$35.91M(+15.9%) | -$156.76M(+2.1%) |
| Jun 2025 | - | -$42.72M(-13.5%) | -$160.09M(+6.2%) |
| Mar 2025 | - | -$37.65M(+7.0%) | -$170.60M(+33.0%) |
| Dec 2024 | -$290.98M(-829.4%) | -$40.49M(-3.2%) | -$254.77M(-20.2%) |
| Sep 2024 | - | -$39.24M(+26.3%) | -$212.04M(-37.9%) |
| Jun 2024 | - | -$53.23M(+56.3%) | -$153.78M(-92.0%) |
| Mar 2024 | - | -$121.81M(-5550.3%) | -$80.08M(-300.7%) |
| Dec 2023 | $39.89M | $2.23M(-88.3%) | $39.89M(+690.4%) |
| Sep 2023 | - | $19.02M(-7.1%) | -$6.76M(+91.6%) |
| Jun 2023 | - | $20.48M(+1207.7%) | -$80.29M(+48.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$1.85M(+95.8%) | -$154.92M(+22.9%) |
| Dec 2022 | -$200.85M(-143.1%) | -$44.41M(+18.5%) | -$200.85M(-8.7%) |
| Sep 2022 | - | -$54.52M(-0.7%) | -$184.74M(-41.9%) |
| Jun 2022 | - | -$54.15M(-13.3%) | -$130.22M(-37.6%) |
| Mar 2022 | - | -$47.78M(-68.9%) | -$94.65M(-58.5%) |
| Dec 2021 | -$82.64M(-106.6%) | -$28.29M(-52.3%) | -$59.73M(-49.2%) |
| Jun 2021 | - | -$18.58M(-44.5%) | -$40.03M(-86.6%) |
| Mar 2021 | - | -$12.86M(-49.7%) | -$21.45M(-149.7%) |
| Dec 2020 | -$39.99M(-221.5%) | -$8.59M | -$8.59M |
| Dec 2019 | -$12.44M | - | - |
FAQ
- What is Amylyx Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Amylyx Pharmaceuticals, Inc.?
- What is Amylyx Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Amylyx Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Amylyx Pharmaceuticals, Inc.?
- What is Amylyx Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Amylyx Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Amylyx Pharmaceuticals, Inc.?
- What is Amylyx Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Amylyx Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of AMLX is -$290.98M
What is the all-time high annual EBITDA for Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals, Inc. all-time high annual EBITDA is $39.89M
What is Amylyx Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, AMLX annual EBITDA has changed by -$330.87M (-829.45%)
What is Amylyx Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of AMLX is -$35.91M
What is the all-time high quarterly EBITDA for Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals, Inc. all-time high quarterly EBITDA is $20.48M
What is Amylyx Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, AMLX quarterly EBITDA has changed by +$3.33M (+8.49%)
What is Amylyx Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of AMLX is -$156.76M
What is the all-time high TTM EBITDA for Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals, Inc. all-time high TTM EBITDA is $39.89M
What is Amylyx Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, AMLX TTM EBITDA has changed by +$55.28M (+26.07%)